ArticleDiscover oncology2025
Low pre-treatment neutrophil-to-lymphocyte ratio predicted a better survival in recurrent/metastatic cervical cancer treated with PD-1/PD-L1 inhibitors.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advancement in inflammatory biomarkers for cervical cancer diagnosis and therapy.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundA precise predictor is urgently needed for immunotherapy in cervical cancer (CC), which would be very helpful for disease monitoring. Thus, we explore the relationship between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and prognosis in recurrent/metastatic CC patients who were treated with PD-1/PD-L1 inhibitors.
methodsA total of 282 patients with recurrent/metastatic cervical cancer were enrolled in this retrospective study from December 2018 to September 2023. The area under the receiver operating characteristic (ROC) curve was used to identify the optimal threshold for evaluating the influence of pre-treatment NLR on patients' survival. Kaplan-Meier analysis was conducted to determine the predictive roles of pre-treatment NLR for progression-free survival of immunotherapy (PFSi) and overall survival (OS).
resultsA pre-treatment NLR = 3.91 was determined to be the optimal cut-off value for predicting patient prognosis, with an AUC of 0.636 (P < 0.05). Patients with a pre-treatment NLR < 3.91 (low-NLR group) exhibited significantly extended PFSi (P < 0.001) and OS (P < 0.001) compared to those with pre-treatment NLR ≥ 3.91 (high-NLR group). Notably, lower pre-treatment NLR was associated with better objective response rate (36.8% vs. 18.3%, P < 0.001). In the stratification analysis, the predictive roles of pre-treatment NLR were mainly found in patients with positive expression of PD-L1 (P = 0.041 for PFSi; P = 0.001 for OS). Moreover, regardless of when the immunotherapy was initiated, a lower pre-treatment NLR correlated with longer survival.
conclusionThe pre-treatment NLR could be a biomarker for predicting the response to anti-PD-1/PD-L1 therapy in recurrent/metastatic CC. In combination with PD-L1 status, it may improve the benefits of immunotherapy and lower the treatment costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.